我们是一间临床阶段的生物医药公司,专注於开发及商业化.PDFVIP

WuXi Ventures [] [] • • A-1A-3 150 • • IND PD-L1(CS1001) • • PD-L1(CS1001) I – 129 – • B262 B • CTLA-4(CS1002)PD-1(CS1003) I • MEK(CS3006) I • BlueprintBlueprint avapritinib CS3007 (BLU-285), CS3008 (BLU-554) CS3009 (BLU-667) • AgiosAgios ivosidenib CS3010 AG-120 • CS1001 PD-L1 II cHLNKTL • INDCS1003 PD-1 • FDATIBSOVO (ivosidenib) Agios • INDCS3006 MEK – 130 – • INDCS1002 CT